News

Panion at EMA's SME InfoDay

Panion has an active status as SME (Small and Medium-sized Enterprise) - at the European Medicines Agency (EMA), which gives access to a number of benefits, information sources, and financial incentives. CEO Anja Holm attended the SME InfoDay on Friday 17 November at the EMA's offices where agency officials together with scientific and regulatory experts from the European Network presented developments and were ready to meet and discuss with companies on an informal basis.

The SME-office provides an amazing amount of support to foster innovation from academia and small research companies and to help the new ideas from "lab-bench to market". Besides guidance in the complex regulatory field, which is caused by the innovative nature of the new development products, the day also revealed changes in the structures of scientific advice and financial opportunities provided by the European Commission and their support programs.

When a company plans their evidence-creating clinical trials, it is possible to get input and advice to ensure that e.g. the parameters measured in the trial are those found most relevant by the authorities. This was demonstrated to clearly improve the probability for a positive outcome of the marketing authorization application and, hence, a product on the market. 

"Panion plans to pursue all the advice we can get that will help us through with our innovative development product for epilepsy in dogs" says Anja Holm.

The InfoDay provided an overview of EU initiatives supporting development stage SMEs. The future EU funding opportunities were highlighted and platforms for early dialogue with regulators from EMA, national authorities and the EU Innovation Network were presented. Specific support to optimize development plans was described together with feedback on experience at stage of marketing authorization. The event was attended by 120 persons from SME companies and 150 more were linked in via webcast, the majority from the human medicines sector.

FRI, NOV 24, 2017

Anja E. H. Holm, CEO
+ 45-22 94 66 00
anja.holm@panion-animalhealth.com

Bolaget ska utveckla och kommersialisera genterapi för behandling av epilepsiliknande tillstånd hos hundar och andra djur, samt utveckla och kommersialisera andra veterinärmedicinska produkter och nya behandlingsformer som kan ge sjuka djur bättre livskvalitet. 
Panion will develop and commercialize a gene therapy treatment for dogs with drug refractory epilepsy, and other new animal health products and treatments that improve the quality of life for animals suffering from chronic diseases. 

2017-12-11

Panion Animal Health AB has received the European Medicines Agency's acceptance of the classification as MUMS (Minor Use Minor Species) for our epilepsy product for both dogs and cats. The request for classification was submitted to the Committee for Medicinal Products for Veterinary Use (CVMP) in the European Medicines Agency (EMA) earlier in 2017 and has now been successfully evaluated. 

2017-12-07

Panion Animal Health AB develops a new epilepsy medicine for dogs based on CombiGene's drug vector CG01. Initial results from CombiGene's long-term study in rats was released yesterday in a message, which is highly relevant for Panion's development of the product for epilepsy in dogs.

2017-11-24

Panion has an active status as SME (Small and Medium-sized Enterprise) - at the European Medicines Agency (EMA), which gives access to a number of benefits, information sources, and financial incentives. CEO Anja Holm attended the SME InfoDay on Friday 17 November at the EMA's offices where agency officials together with scientific and regulatory experts from the European Network presented developments and were ready to meet and discuss with companies on an informal basis.

2017-11-21

Period July-September 

  • Net sales: kSEK 0 (0)
  • Operating profit: kSEK -923 (-43)
  • Earnings per share: SEK -0,25 (-0,01)
  • Liquidity at the end of the period: kSEK 1 166 (541)

Period January-Sept 

  • Net sales: kSEK 0 (0).
  • Operating profit: kSEK -3 501 (-43)
  • Earnings per share: SEK -0,25 (-0,01)
  • Liquidity at the end of the period: kSEK 1 166 (541)
1
2
3
4
5
6

Subscribe

Press releases and reports via E-mail.